Evaluating treatments for severe community-acquired pneumonia in ICU patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial, known as REMAP-CAP, is designed to evaluate the effectiveness of various treatment strategies for patients admitted to the intensive care unit with severe community-acquired pneumonia. It employs a multifactorial adaptive platform approach, allowing for the simultaneous assessment of multiple therapies, including antibiotics and supportive care. The trial is structured to utilize data from ongoing patients to inform treatment decisions for new participants, enhancing the likelihood of beneficial outcomes. Additionally, it includes a sub-platform specifically for COVID-19 treatments, adapting to the needs of respiratory pandemics.

Why it matters

Who can join: the full rules

The eligibility criteria for the Platform are applied at multiple levels. One level is that there are inclusion and exclusion criteria that determine eligibility for randomization within the Platform. Another level is that, once eligible for inclusion within the Platform, additional criteria (typically exclusion criteria) are applied that are specific to each domain. Finally, intervention-level eligibility criteria may be applied for interventions within a domain. A patient is eligible for inclusion within a domain when:

* All Platform inclusion criteria are met
* None of the Platform exclusion criteria are met
* Domain-specific eligibility criteria are met
* The patient is eligible for at least two interventions within a domain

As such, the key "inclusion criteria" for being eligible for a domain are that the patient is eligible for the Platform.

\--

PLATFORM INCLUSION CRITERIA:

1. Hospitalised patient
2. Acute respiratory tract infection
3. Aged 28 days or older

PLATFORM EXCLUSION CRITERIA:

1. Death is deemed to be imminent and inevitable during the next 24 hours AND one or more of the patient, substitute decision maker or attending physician are not committed to full active treatment
2. Patient is expected to be discharged from hospital within the next 24 hours
3. Previous participation in this REMAP within the last 90 days

DOMAIN-SPECIFIC ELIGIBILITY CRITERIA:

Each domain may have additional eligibility criteria. Refer to the study website for more information (www.remapcap.org).

Where it's running

• University of Florida
  Jacksonville, Florida, United States Recruiting
• University of Illinois Health
  Chicago, Illinois, United States Recruiting
• University of Michigan
  Ann Arbor, Michigan, United States Recruiting
• Memorial Sloan Kettering Cancer Center
  New York, New York, United States Recruiting
• The Ohio State University Wexner Medical Center
  Columbus, Ohio, United States Recruiting
• Oregon Health and Science University
  Portland, Oregon, United States Recruiting

+358 more sites. See ClinicalTrials.gov for the full list.

Study contacts

• Study coordinator: Cameron Green, MSc
• Email: info@remapcap.org

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparative Immunogenicity of Respiratory Virus Vaccines (CIRV2) in Adults

  This study tests and compares the immune responses and tolerability of the latest COVID-19 vaccines from Novavax and Pfizer/BioNTech in adults at risk for severe COVID-19.

  Recruiting Phase 4 Henry M. Jackson Foundation for the Advancement of Military Medicine · Bethesda, Maryland · NCT07287137

• Virological Monitoring of Seasonal Respiratory Infections in France

  This project tests how often common respiratory viruses show up in patients seen by primary care doctors in metropolitan France during the fall and winter.

  Recruiting Institut National de la Santé Et de la Recherche Médicale, France · Paris · NCT07599449

• Study on influenza and COVID-19 effects in pregnant women in India

  This study is testing how getting both COVID-19 and influenza affects pregnant women and their babies, while also looking at how vaccinations might help reduce risks during pregnancy.

  Recruiting at 2 sites Boston University · Boston, Massachusetts and 1 other locations · NCT06168019

• Remdesivir to prevent severe COVID-19 in kidney transplant patients

  This study will try giving remdesivir around the time of transplant to see if it prevents severe COVID-19 in adults receiving a kidney transplant who are currently SARS‑CoV‑2 positive with no or mild symptoms.

  Recruiting Phase 2 Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia · Badalona, Barcelona · NCT07197164

• Understanding how brain changes relate to smell disorders over time

  This small, year-long study tests how brain activity and smell-related inflammation relate to different smell disorders in adults.

  Recruiting National Institutes of Health Clinical Center (CC) · Bethesda, Maryland · NCT07149428

• Monitoring and detection of influenza, RSV, and COVID-19 in adults with and without HIV in Lusaka

  This project will test methods to detect influenza, RSV, and COVID-19 in adults with and without HIV who have recent respiratory symptoms in Lusaka.

  Recruiting at 2 sites Centre for Infectious Disease Research in Zambia · Lusaka, Lusaka Province and 1 other locations · NCT07030075

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.